Invivyd, Inc.IVVDEarnings & Financial Report
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
IVVD Q4 FY2025 Key Financial Metrics
Revenue
$17.2M
Gross Profit
N/A
Operating Profit
$-12.6M
Net Profit
$-11.1M
Gross Margin
N/A
Operating Margin
-73.0%
Net Margin
-64.3%
YoY Growth
24.5%
EPS
$0.02
Invivyd, Inc. Q4 FY2025 Financial Summary
Invivyd, Inc. reported revenue of $17.2M (up 24.5% YoY) for Q4 FY2025, with a net profit of $-11.1M (up 40.0% YoY) (-64.3% margin).
Key Financial Metrics
| Total Revenue | $17.2M |
|---|---|
| Net Profit | $-11.1M |
| Gross Margin | N/A |
| Operating Margin | -73.0% |
| Report Period | Q4 FY2025 |
Invivyd, Inc. Annual Revenue by Year
Invivyd, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $53.4M).
Invivyd, Inc. Quarterly Revenue & Net Profit History
Invivyd, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $17.2M | +24.5% | $-11.1M | -64.3% |
| Q3 FY2025 | $13.1M | +41.2% | $-10.5M | -79.7% |
| Q2 FY2025 | $11.8M | +420.6% | $-14.7M | -124.4% |
| Q1 FY2025 | $11.3M | — | $-16.3M | -144.1% |
| Q4 FY2024 | $13.8M | — | $-18.4M | -133.5% |
| Q3 FY2024 | $9.3M | — | $-60.7M | -653.1% |
| Q2 FY2024 | $2.3M | — | $-47.2M | -2086.9% |
| Q1 FY2024 | $0 | — | $-43.5M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $2.3M | $9.3M | $13.8M | $11.3M | $11.8M | $13.1M | $17.2M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 420.6% | 41.2% | 24.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $215.5M | $177.3M | $161.9M | $129.5M | $103.7M | $89.1M | $139.2M | $276.9M |
| Liabilities | $37.0M | $36.7M | $78.8M | $62.0M | $49.6M | $46.3M | $46.1M | $35.3M |
| Equity | $178.5M | $140.6M | $83.2M | $67.5M | $54.1M | $42.8M | $93.1M | $241.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-50.2M | $-41.6M | $-41.1M | $-37.6M | $-21.1M | $-13.3M | $-8.3M | $-15.5M |